CVS Health Corp. (CVS) on Decifer

Why it ranks here

Its returns on invested money are modest, around 5% and it turns most of its profit into real cash.
Revenue is growing about 8% a year, profits are expected to grow 13%, and growth is speeding up, not slowing down.
It keeps a thin share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
It is riding an active market tailwind but its balance sheet leaves little room to fund growth.
It is not watering down its owners with new shares.
Our durability check found pressure on this name, which costs it a few points.
It trades about 88% above similar companies, and its growth does not yet back up that price.

The current read

The evidence on CVS lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

Healthcare, Biotech & Devices: CVS Health Corporation sits in the distribution & pbm layer of the Healthcare, Biotech & Devices story.
GLP-1 & Metabolic Health: CVS Health operates a pharmacy benefit manager (Caremark), retail pharmacy, and insurance (Aetna) business. GLP-1 drugs are dispensed through CVS pharmacies and managed through Caremark PBM — rising GLP-1 volumes drive prescription revenue and PBM processing fees. CVS's integrated health services model (MinuteClinics, home health) benefits from the broader metabolic health trend.

Read the full CVS research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.